Visit Contract Pharma
at Booth 1815

Grand River Continues to Expand Sterile Injectable Capabilities


President & CEO Tom Ross talks personnel growth and expansion plans

Since their launch in 2011, Grand River Aseptic Manufacturing has been working with clients to develop and manufacture sterile, injectable drug products. 

Tom Ross, the company's president and chief executive officer, spoke with Contract Pharma at CPhI North America 2018 about the exponential growth he has seen within his company, which started with 16 employees and is now up to 183. He also discussed a major expansion after closing on a large capital raise with Arlington Capital Partners.

The expansion will consist of a large fill/finsh facility with multiple cleanrooms, and will be over 40,000 sq. ft. Grand River has also recently acquired a new syringe filler, which is expected to go live at their facility in the summer of 2020.